Clinical trial · Observational
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
A Multicenter Real-World Data Pooled Analysis: The Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage III non-small cell lung cancer (NSCLC) patients from multiple tertiary hospitals in real-world settings since August 2020 being collected and analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC Stage IIIB, NSCLC Stage IIIC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tislelizumab Combined with Chemotherapy, | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- major pathological response
- timeFrame
- ;usually 1 week after surgery
- description
- viable tumor cell less than 10%
Secondary outcomes (6)
- measure
- R0 resection rate
- timeFrame
- ,usually 1 week after surgery
- description
- margin negative resection
- measure
- Down-staging rate
- timeFrame
- usually 1 week after surgery
- description
- clinical and pathological downstaging
- measure
- Impact of Neoadjuvant Therapy on Surgical Outcomes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system. Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations. No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered. ECOG PS scores of the enrolled patients ranged from 0 to 2. Exclusion Criteria: Patients with other previous malignancies did not require additional treatment. Patients with incomplete key baseline and treatment information:including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant. Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.
References
Publications (0)
Data not yet available